GlobeNewswire

Parabilis Medicines to Participate in Upcoming November Investor Conferences
03/11/2026
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by [...]
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
03/11/2026
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology & [...]
Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
03/11/2026
Q3 2026 net revenues increased 4.4% on both an as-reported and constant currency basis (1) , compared to Q3 2025 Q3 2026 net income of $58 million or $0.20 per diluted share Q3 2026 Adjusted EBITDA ( 1 ) increased 3.9 [...]
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
03/11/2026
MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
03/11/2026
– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation – – Reaffirmed commitment to share clinical data from three Phase 1 [...]
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
03/11/2026
-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 net product revenue [...]
C4 Therapeutics to Participate in Upcoming November Investor Conferences
03/11/2026
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today [...]
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
03/11/2026
Third-quarter 2026 Rezdiffra ® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability Rezdiffra reaches a major milestone, achieving blockbuster [...]
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
03/11/2026
CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
03/11/2026
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Cardiff Oncology to Participate in the UBS Global Biopharma Conference
03/11/2026
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced [...]
Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors
03/11/2026
Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy and operational execution appointed to lead company into new phase of clinical [...]
Maze Therapeutics to Participate in Upcoming Investor Conferences
03/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney [...]
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/11/2026
NEW HAVEN, Conn., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on November 1, 2026, Invivyd granted seven newly hired non-executive employees options to purchase an aggregate of [...]
Why Fat Transfer Breast Enlargement Is Trending in Dubai
03/11/2026
DUBAI, United Arab Emirates, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Fat transfer breast enlargement in Dubai is becoming increasingly popular among individuals seeking to increase their breast size while retaining a natural [...]
Kailera Therapeutics to Participate in November Investor Conferences
03/11/2026
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron [...]
Decoy Therapeutics Provides Third Quarter 2026 Business Update
03/11/2026
Lead pan-coronavirus program expected to file CTA/IND in 2H 2027 Optimized lead candidate shows potential for once-weekly dosing in preclinical studies Cash on balance sheet of $8.1 million at September 30, 2026 [...]
Beta Bionics Announces Participation at Upcoming Investor Conferences
03/11/2026
IRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will participate at [...]
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
03/11/2026
WAYNE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum